AlphaCentric Advisors’s Protagonist Therapeutics PTGX Stock Holding History

AlphaCentric Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.35M	Buy	9,616 +445	+5%	+$63.4K	1.2%	14
2026 Q2	$1.12M	Buy	9,171 +131	+1%	+$13.7K	0.95%	21
2026 Q1	$953K	Buy	9,040 +491	+6%	+$43.5K	0.95%	22
2025 Q4	$747K	Buy	+8,549	New	+$700K	0.74%	36
2024 Q4	$275K	Sell	7,123 -17,877	-72%	-$779K	0.27%	92
2024 Q3	$1.12M	Hold	25,000	–	–	0.84%	42
2024 Q2	$866K	Hold	25,000	–	–	0.64%	56
2024 Q1	$723K	Sell	25,000 -5,000	-17%	-$136K	0.44%	75
2023 Q4	$688K	Sell	30,000 -13,500	-31%	-$236K	0.46%	64
2023 Q3	$726K	Buy	+43,500	New	+$844K	0.41%	77

Other funds holding PTGX

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

AlphaCentric Advisors's PTGX Position: Q3 2026 in Review

AlphaCentric Advisors increased its Protagonist Therapeutics (PTGX) stake by 4.9% in Q3 2026, buying an estimated $63.4K and bringing the position to 9,616 shares worth $1.35M. The position accounts for 1.2% of the portfolio, ranked #14.

AlphaCentric Advisors first reported a position in PTGX in Q3 2023 and has held it in 10 quarters since. 123 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

AlphaCentric Advisors held 9,616 shares of Protagonist Therapeutics worth $1.35M as of Q3 2026.
AlphaCentric Advisors bought 445 Protagonist Therapeutics shares in Q3 2026, an estimated $63.4K.
Protagonist Therapeutics made up 1.2% of AlphaCentric Advisors's portfolio in Q3 2026, its #14 holding.
AlphaCentric Advisors first reported a position in Protagonist Therapeutics in Q3 2023 and has held it in 10 quarters since.
123 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.